Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

• Status: Recruiting
• Trial end date: 2022-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This is an explorative, proof-of-concept study exploring the potential therapeutic role of a Liraglutide-based weight loss regimen versus standard CPAP or the combination of both on metabolic parameters, blood pressure, endothelial function, coronary artery calcification, vascular inflammation and apnea/hypopnea index in non-diabetic patients with moderate to severe obstructive sleep apnea

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St Vincent's University Hospital, Ireland
• Collaborators: Health Research Board, Ireland; University College Dublin
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Newly diagnosed moderate-severe OSA (by standard PSG)

• Body mass index between 30 - 40

• Age 18 - 60 years

• Able to provide written, informed consent

Exclusion Criteria:

• Pregnancy

• Requirement for supplemental oxygen

• Previous diagnosis of OSA or previous CPAP treatment

• Diagnosis of Diabetes

• Previous treatment with GLP-1 analogue

• Previous surgical treatment for obesity

• Active treatment for malignancy or severe psychiatric disorder

• Acute coronary syndrome or stroke within 3 months prior to study

• History of decompensated heart failure

• Professional drivers or drivers with a history of road-traffic accident due to sleepiness

• Severe excessive daytime sleepiness defined as Epworth sleepiness scale >15